Stimulation with β-ionone dose-dependently activates ERK1/2 with an EC50 value of about 20 μM, and its efficiency is comparable to other GPCR agonists tested and LPS in two prostate cancer cell lines. Here, MAPK3 is linked to Familial prostate cancer.